Genome editing advances drug discovery in biomedical research.

A Novartis experimental drug in clinical trial aims to block liver cancer growth

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.

The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.

Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges.